Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06063850 · ClinicalTrials.gov registry record · Phase 1
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
A Phase 1 study of Mesial Temporal Lobe Epilepsy, sponsored by UniQure Biopharma B.V..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 18
- Study locations
NCT06063850 is a Phase 1 study of Mesial Temporal Lobe Epilepsy that is actively recruiting participants, run by UniQure Biopharma B.V.. The registered enrollment target is 12 participants. The trial reports 18 study locations across 14 states.
The verdict
NCT06063850, a Phase 1 study of Mesial Temporal Lobe Epilepsy, is actively recruiting participants, sponsored by UniQure Biopharma B.V..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 18
- Study locations
Study Summary
The main goals of this clinical study are to learn if AMT-260 is safe and tolerable and works to reduce the frequency of seizures in adults with unilateral mesial temporal lobe epilepsy (MTLE).
Conditions Studied
Interventions
- GENETIC AAV9-hSyn1-miGRIK2
Study Locations (18)
Maryland
- Johns Hopkins School of Medicine - Baltimore
- Midatlantic Epilepsy and Sleep Center - Bethesda
New Jersey
- Northeast Regional Epilepsy Group - Hackensack
- Robert Wood Johnson Hospital - New Brunswick
Ohio
- Cleveland Clinic - Cleveland
- Ohio State University - Columbus
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
- Allegheny Health Network - Pittsburgh
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic Arizona - Phoenix
California
- Stanford University - Palo Alto
Florida
- Mayo Clinic Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-06-12 |
| Est. Completion | 2031-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06063850
The ClinicalTrials.gov registry entry for NCT06063850 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UniQure Biopharma B.V., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mesial Temporal Lobe Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which AAV9-hSyn1-miGRIK2 is the first listed.
NCT06063850 reports 18 study locations spanning 14 distinct geographic areas - top geographies include Maryland, New Jersey, Ohio.
Frequently Asked Questions
What is clinical trial NCT06063850 about?
NCT06063850 is a clinical study titled "AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy". The main goals of this clinical study are to learn if AMT-260 is safe and tolerable and works to reduce the frequency of seizures in adults with unilateral mesial temporal lobe epilepsy (MTLE).
What is the current status of trial NCT06063850?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-06-12. Estimated completion is 2031-12.
What conditions does trial NCT06063850 study?
This clinical trial studies the following conditions: Mesial Temporal Lobe Epilepsy.
What interventions are being tested in trial NCT06063850?
The interventions under investigation include: AAV9-hSyn1-miGRIK2 (GENETIC).
Who is sponsoring clinical trial NCT06063850?
This trial is sponsored by UniQure Biopharma B.V., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06063850 being conducted?
This trial has 18 study locations across Alabama, Arizona, California, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mesial Temporal Lobe Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.